Some interesting news from the New Drugs Development:
"Medigene signs licence agreement with Falk Pharma for RhuDex® in hepatology and gastroenterology"
"Dr. Falk Pharma GmbH to fund all costs for development and commercialization of RhuDex® in the indication areas hepatology and gastroenterology"
"Medigene eligible for an upfront payment, milestone payments plus double-digit royalties
Falk Pharma will initially concentrate on development in primary biliary cirrhosis (PBC)
Medigene retains RhuDex® rights for rheumatoid arthritis and other autoimmune diseases"
"About RhuDex: RhuDex® is being developed by Medigene as a first-in-class modifying agent for the oral treatment of autoimmune diseases. Autoimmune diseases are characterized by the inappropriate activation of immune reactions against autologous tissue. Activation and proliferation of such auto-reactive T-cells and the resultant release of inflammatory mediators plays a major role in the pathogenesis and course of auto-immune diseases. Pivotal in this process is the interaction of the CD28 protein receptor on the surface of T-cells with the CD80 protein on the surface of other immune cells. RhuDex® has the ability to bind to CD80, thus preventing interaction with CD28. By doing so, an important signaling pathway of T-cell activation is blocked. The safety and tolerability of RhuDex® has been demonstrated in a number of phase I clinical trials. In the indication rheumatoid arthritis Medigene successfully concluded a phase IIa pilot trial."
Here is the Link:
